FrancophonIA/ELRC3.0 huggingface dataset:
English: BMI is a measure of your weight in relation to your height.Type 1 diabetes is a disease where your body's immune system destroys the insulin-producing cells in the pancreas and the body produces little to no insulin, the hormone that normally controls the level of your blood sugar.
Slovenian: Sladkorna bolezen tipa 1 je bolezen, pri kateri lastni imunski sistem telesa uniči celice, v katerih v trebušni slinavki nastaja insulin.
English: Sotagliflozin is not recommended in patients with moderate and severe hepatic impairment (see sections 4.4 and 5.2).
Slovenian: Za bolnike z zmerno in hudo jetrno okvaro sotagliflozin ni priporočljiv (glejte poglavji 4.4 in 5.2).
English: Hypotension/ volume depletion
Slovenian: Hipotenzija/hipovolemija
English: You should not take this medicine if you are breast-feeding.
Slovenian: Če dojite, tega zdravila ne smete jemati.
English: In the study 52% were male and 96.2% were White and 87% of randomised patients completed the study.
Slovenian: V kliničnem preskušanju je bilo 52 % moških in 96,2 % belcev; klinično preskušanje je dokončalo 87 % randomiziranih bolnikov.
English: Initiation of sotagliflozin is not recommended when eGFR is less than 60 ml/min/1.73 m2 and should be discontinued if eGFR is persistently less than 45 mL/min/1.73 m2 (see sections 4.4 and 4.8).
Slovenian: Sotagliflozina ni priporočljivo uvesti, če je eGFR manj kot 60 ml/min in ga je potrebno ukiniti če je, če je eGFR manj kot 45 ml/min/1,73 m2 (glejte poglavje 4.2 in 4.8).
English: Mean change from baseline at week 52
Slovenian: Povprečna sprememba od izhodišča 52. teden
English: Mean change from baseline at week 24
Slovenian: Povprečna sprememba od izhodišča 24. teden
English: The exposure-adjusted incidence rate was 3.12, 4.19 and 0.21 subjects per 100 patient-years for sotagliflozin 200 mg, sotagliflozin 400 mg and placebo.
Slovenian: Za izpostavljenost prilagojeni incidenčni deleži so bili 3,12, 4,19 in 0,21 preiskovanca na 100 bolnikov-let za 200 mg sotagliflozina, 400 mg sotagliflozina in placebo.
English: 100 film-coated tablets
Slovenian: Filmsko obložena tableta 100 filmsko obloženih tablet
English: Clinical stage
Slovenian: KLINIČNI PODATKI
English: Be aware that either uro-genital infection or perineal abscess may precede necrotizing fasciitis.
Slovenian: Vedeti morate, da se lahko pred nekrotizirajočim fascitisom pojavi urogenitalna okužba ali perinealni absces.
English: • dehydration (losing too much water from your body, symptoms include dry mouth, feeling dizzy,
Slovenian: • dehidracija (prekomerna izguba vode iz telesa; med simptomi so suhost ust, omotica, vrtoglavica ali šibkost, zlasti ko vstanete, omedlevica)
English: - Printing ink: shellac; iron oxide black (E172); propylene glycol.
Slovenian: - Barva za napis: šelak, črni železov oksid E172, propilenglikol.
English: * See section 4.4 † See subsections below for additional information.
Slovenian: † Za dodatne informacije glejte podpoglavja spodaj.
English: In a pre-specified pooled analysis of study 1 and study 2, treatment with sotagliflozin as adjunct to insulin resulted in a reduction of SBP (-0.6 mmHg for placebo, -2.6 mmHg for sotagliflozin 200 mg and -4.1 mmHg for sotagliflozin 400 mg) at week 12.
Slovenian: V vnaprej določeni združeni analizi podatkov študije 1 in študije 2 je zdravljenje s sotagliflozinom kot dodatkom insulinu po 12 tednih doseglo znižanje SKT (-0,6 mmHg s placebom, -2,6 mmHg z 200 mg sotagliflozina in -4,1 mmHg s 400 mg sotagliflozina).
English: This treatment is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with T1DM with a BMI ≥27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.
Slovenian: To zdravilo je indicirano kot dodatek zdravljenju z insulinom za izboljšanje urejenosti glikemije pri odraslih s sladkorno boleznijo tipa 1 in ITM ≥ 27 kg/m2, ki kljub optimalnemu zdravljenju z insulinom niso dosegli ustrezne urejenosti glikemije.
English: Zynquista 200 mg film-coated tablets (tablets) are oval, blue, with “2456” on one side printed in black ink (tablet length: 14.2 mm, tablet width: 8.7 mm).
Slovenian: Filmsko obložene tablete (tablete) zdravila Zynquista 200 mg so ovalne oblike in modre barve ter imajo na eni strani s črnim črnilom natisnjeno oznako "2456" (dolžina tablete: 14,2 mm, širina tablete:
English: • if you have an infection of the kidney or the urinary tract.
Slovenian: • če imate okužbo ledvic ali sečil.
English: Animal studies do not indicate direct or indirect harmful effects with respect to fertility and pregnancy (see section 5.3).
Slovenian: Študije na živalih ne kažejo neposrednih ali posrednih škodljivih učinkov na plodnost in nosečnost
English: Frequency of occurrence Very common Common
Slovenian: Pogostnost pojavljanja
English: Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.
Slovenian: Zdravilo Zynquista je indicirano kot dodatek zdravljenju z insulinom za izboljšanje urejenosti glikemije pri odraslih s sladkorno boleznijo tipa 1 z indeksom telesne mase (BMI)) ≥ 27 kg/m2, ki kljub optimalnemu zdravljenju z insulinom ne dosegajo primerne urejenosti glikemije.
English: *Systolic blood pressure was assessed at week 16 † p <0.001 ‡ p=0.002
Slovenian: *Sistolični krvni tlak so ocenili po 16 tednih
English: • Patients with euglycaemic DKA should receive glucose, insulin and fluids for DKA, sotagliflozin should be discontinued.
Slovenian: • Bolniki z evglikemično DKA morajo prejemati glukozo, insulin in tekočine za DKA, zdravljenje s sotagliflozinom pa je treba prekiniti.
English: Study 3 InTandem 3 (study 3) was a 24-week duration study performed on a background of existing insulin regimen in type 1 diabetes patients with screening HbA1c ≥7.0% to ≤11.0%, to evaluate efficacy and safety of sotagliflozin 400 mg once daily versus insulin alone.
Slovenian: Klinično preskušanje InTandem 3 (študija 3) je bila 24-tedenska študija, izvedena v okoliščinah obstoječe insulinske sheme pri bolnikih s sladkorno boleznijo tipa 1, ki so imeli ob presejanju HbA1c od ≥ 7,0 % do ≤ 11,0 %.
English: The incidence of renal-related events was low and similar across the groups (1.5%, 1.5% and 1.3% for sotagliflozin 200 mg, sotagliflozin 400 mg and placebo).
Slovenian: Pojavnost z ledvicami povezanih dogodkov je bila majhna in med skupinami podobna (1,5 % z 200 mg sotagliflozina, 1,5 % s 400 mg sotagliflozina in 1,3 % s placebom).
English: Table 3: Changes from baseline in serum creatinine and eGFR in the pool of two 52-week placebocontrolled studies
Slovenian: Preglednica 3: Spremembe kreatinina v serumu in eGFR od izhodišča; združeni podatki dveh
English: Treatment with sotagliflozin also resulted in reduction in body weight and bolus insulin dose compared with insulin alone (see Table 6).
Slovenian: Zdravljenje s sotagliflozinom je v primerjavi s samim insulinom povzročilo tudi zmanjšanje telesne mase in odmerka bolusnega insulina (glejte preglednico 6).
English: Pharmacotherapeutic group: Drugs used in diabetes, sodium-glucose co-transporter 2 (SGLT2) inhibitors, ATC code: A10BK06
Slovenian: Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, zaviralci od natrijevih ionov odvisnega glukoznega soprenašalca 2 (SGLT2).
English: Monitoring of renal function is recommended as follows: - Prior to initiation of sotagliflozin and monitored periodically, at least yearly, thereafter (see section 4.2).
Slovenian: - Pred uvedbo sotagliflozina in nato redno vsaj enkrat na leto (glejte poglavje 4.2).
English: Check your ketones regularly during the first two weeks after starting Zynquista.
Slovenian: Prva dva tedna po začetku jemanja zdravila Zynquista redno kontrolirajte ketone.
English: The risk of diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness.
Slovenian: Če se pojavijo nespecifični simptomi, kot so navzea, bruhanje, neješčnost, bolečine v trebuhu, prekomerna žeja, težko dihanje, zmedenost, neobičajna utrujenost ali zaspanost, je treba upoštevati možnost diabetične ketoacidoze.
English: • ZYNQUISTA should be temporarily stopped before surgical procedures or hospitalisation for acute serious illness.
Slovenian: • Uporabo zdravila Zynquista je treba začasno prekiniti pred operacijami ali ob sprejemu v bolnišnico zaradi akutne resne bolezni.
English: The patient should go to emergency department without delay and stop taking sotagliflozin.
Slovenian: Bolnik se mora nemudoma oglasiti v ambulanti za nujno medicinsko pomoč in prenehati jemati sotagliflozin.
English: o nausea, vomiting, or abdominal pain o excessive thirst o constantly feeling tired o high levels of ketones in urine tests or beta-hydroxybutyrate (BHB) in blood tests o difficulty breathing/rapid, deep breathing o breath with fruity odour o difficulty paying attention, or confusion o rapid weight loss.
Slovenian: o visoka koncentracija ketonov v testih urina ali betahidroksibutirata (BHB) v krvi o težko dihanje/hitro, globoko dihanje, o sadni vonj izdihanega zraka o težave z zbranostjo ali zmedenost, o hitro hujšanje.
English: In a 12 week dose ranging study, consistent with SGLT1 inhibition, placebo corrected change from baseline 2-hour post prandial glucose (PPG), measured after a standardised mixed meal, was reduced by 1.52 mmol/L (p=0.15) and 2.73 mmol/L (p=0.006) in patients taking 200 mg and 400 mg sotagliflozin respectively, which is consistent with SGLT1 inhibition.
Slovenian: Znižanje postprandialne glukoze V 12-tedenskem preskušanju odmerjanja se je (skladno z zavrtjem SGLT1) za placebom popravljena postprandialna glukoza (PPG) 2 uri po standardiziranem mešanem obroku v primerjavi z izhodiščem znižala za 1,52 mmol/l (p = 0,15) pri bolnikih, ki so prejemali 200 mg sotagliflozina in za 2,73 mmol/l (p = 0,006) pri bolnikih, ki so prejemali 400 mg sotagliflozina; kar je skladno z zaviranjem SGLT1.
English: Pharmacologically-related reversible renal changes were observed in a rat postnatal study, corresponding to the second and third trimesters of human pregnancy (see section 5.3).
Slovenian: Pri podganah so v postnatalni študiji opazili farmakološko pogojene, reverzibilne ledvične spremembe med obdobjem, ki ustreza drugemu in tretjemu trimesečju nosečnosti pri človeku (glejte poglavje 5.3), zato sotagliflozin v drugem in tretjem trimesečju nosečnosti ni priporočljiv.
English: In a pre-/post-natal development study, no sotagliflozin-related adverse effects in pregnant and lactating females and offspring development were observed in rats In a study evaluating the potential effects of sotagliflozin on the development of juvenile rats, no sotagliflozin-related toxicity was observed following the administration of oral doses up to approximately 18 and 31 fold that of the MRHD (400 mg/day) for males and females, respectively.
Slovenian: V študiji možnih učinkov sotagliflozina na razvoj mladih podgan niso opazili s sotagliflozinom povezanih toksičnih učinkov po uporabi peroralnih odmerkov, ki so bili pri samcih približno 18-krat in pri samicah približno 31-krat tolikšni kot MRHD (400 mg/dan).
English: From study 1 and study 2, 278 subjects participated in a blinded continuous glucose monitoring (CGM) sub-study (see Table 5).
Slovenian: Podštudija stalnega spremljanja glukoze (CGM): 2-urna postprandialna glukoza in čas v območju 2.278 preiskovancev iz študije 1 in študije 2 je sodelovalo v podštudiji na slepo stalnega spremljanja glukoze (CGM - continuous glucose monitoring) (glejte preglednico 5).
English: Mean terminal T1/2 ranged from 21 to 35 hours for sotagliflozin and from 19 to 26 hours for M19.
Slovenian: do 35 ur in M19 od 19 do 26 ur.
English: Zynquista 200 mg tablets sotagliflozin
Slovenian: Zynquista 200 mg tablete sotagliflozin
English: PVC/PCTFE/Aluminium opaque blisters.
Slovenian: Motni pretisni omoti iz PVC/PCTFE/aluminija.
English: The HbA1c reduction observed in patients with eGFR ≥60 to <90 mL/min/1.73 m2 was comparable to the HbA1c reduction observed in patients with eGFR ≥90 mL/min/1.73 m2.
Slovenian: HbA1c pri bolnikih z eGFR od ≥ 60 do < 90 in ≥ 90 ml/min/1,73 m2 je bilo primerljivo kot pri bolnikih z eGFR ≥ 90 ml/min/1,73 m2 Pri bolnikih z eGFR < 60 ml/min/1,73 m2 so opazili številsko zmanjšanje HbA1c.
English: At screening the HbA1c was 8.21%, 8.26% and 8.20% for insulin, insulin+sotagliflozin 200 mg and insulin+sotagliflozin 400 mg.
Slovenian: Ob presejanju je bil HbA1c v skupini z insulinom 8,21%, v skupini z insulinom + 200 mg sotagliflozina 8,26% ter v skupini z insulinom + 400 mg sotagliflozina je bil HbA1c 8,20 %.
English: Due to the limited therapeutic experience in patients aged 75 years and older, initiation of sotagliflozin therapy is not recommended.
Slovenian: 75 let ali več, uvedba zdravljenja s sotagliflozinom v tej starostni skupini ni priporočljiva.
English: Post-Baseline LS means, LS mean differences, 95% CLs, and p-values for each individual study were obtained from accounting for missing data *p <0.001 † p 0.12 ‡ p=0.034
Slovenian: Izhodiščna povprečna vrednost po mNK, povprečne razlike po mNK, 95 % IKr in vrednosti p za vsako posamezno študijo so dobljeni z upoštevanjem manjkajočih podatkov
English: In a pre-specified pooled analysis of study 1 and study 2, treatment with sotagliflozin as adjunct to insulin resulted in LS mean changes from baseline in FPG of -0.56 mmol/l for sotagliflozin 200 mg and -0.87 mmol/l for sotagliflozin 400 mg compared to insulin alone (0.32 mmol/l) at week 24.
Slovenian: V vnaprej določeni združeni analizi podatkov študije 1 in študije 2 je zdravljenje s sotagliflozinom kot dodatkom insulinu po 24 tednih doseglo povprečno spremembo glukoze v plazmi na tešče po mNK v primerjavi z izhodiščem za -0,56 mmol/l z 200 mg sotagliflozina in za -0,87 mmol/l s 400 mg sotagliflozina v primerjavi s samim insulinom (0,32 mmol/l).
English: In the clinical trials (pool of two 52-week placebo-controlled trials) of sotagliflozin, the incidence of diabetic ketoacidosis (DKA) was higher in the sotagliflozin treatment group compared with the placebo group (see section 4.8).
Slovenian: sotagliflozina je bila pojavnost diabetične ketoacidoze (DKA) v skupini prejemnikov sotagliflozina večja kot v skupini prejemnikov placeba (glejte poglavje 4.8).
English: The incidence of UTI in female subjects was 12%, 7.0% and 11% and the incidence of UTI in male subjects was 2.3%, 4.0% and 1.8% for sotagliflozin 200 mg, sotagliflozin 400 mg and placebo, respectively.
Slovenian: Pojavnost okužb sečil pri preiskovankah je bila 12 %, 7,0 % in 11 % pri preiskovancih pa 2,3 %, 4,0 % in 1,8 % z 200 mg sotagliflozina, s 400 mg sotagliflozina in s placebom.
English: The proportion of patients with A1C <7.0% at 24 weeks was 19.0% for placebo, 35.1% for sotagliflozin 200mg, 40.4% for sotagliflozin 400mg and at 52 weeks was 18.3%, 28.6% and 31.6% for placebo, sotagliflozin 200 mg and 400 mg respectively.
Slovenian: Po 24 tednih se je HbA1c znižal za -0,36 % in za -0,38 % in po 52 tednih za -0,23 % in za -0,32 % s sotagliflozinom 200 mg in 400 mg; delež bolnikov z A1C < 7,0 % je bil po 24 tednih 19 % za placebo, 35,1 % za sotagliflozin 200 mg, 40,4 % za sotagliflozin 400 mg in po 52 tednih 18,3 % za placebo, 28,6 % z 200 mg in 31,6 % s 400 mg sotagliflozina.
English: An increase in cases of lower limb amputation (primarily of the toe) has been observed in ongoing long-term, clinical studies with another SGLT2 inhibitor.
Slovenian: V potekajočih dolgotrajnih kliničnih preskušanjih z nekim drugim zaviralcem SGLT2 so opazili številne primere amputacij spodnjih okončin (predvsem prstov nog).
English: How to store Zynquista
Slovenian: Shranjevanje zdravila Zynquista
English: After initiating sotagliflozin ketones should be monitored on a regular basis during the initial one to two weeks, then the frequency of ketone level testing should be individualised, according to the patient's lifestyle and/or risk factors.
Slovenian: pogostnost kontrol koncentracije ketonov je treba prilagoditi individualno, glede na bolnikov življenjski slog in/ali dejavnike tveganja.
English: Diabetic ketoacidosis*' †
Slovenian: Presnovne in prehranske motnje diabetična ketoacidoza*' †
English: The mean BMI was 30 kg/m2 and 23% of patients had SBP ≥ 130 mmHg.
Slovenian: Povprečni ITM je bil 30 kg/m2 in 23 % bolnikov je imelo SKT ≥ 130 mmHg.
English: Elderly patients
Slovenian: Starejše osebe
English: In the 3 Phase 3 randomized clinical studies in patients with type 1 diabetes, patients with eGFR < 45 mL/min/1.73 m2 were excluded, 79 patients exposed to sotagliflozin had an eGFR < 60 mL/min/1.73 m2 and 841 patients had an eGFR ≥ 60 to ≤ 90 mL/min/1.73 m2.
Slovenian: Tri randomizirane klinične študije 3. faze pri bolnikih s sladkorno boleznijo tipa 1 niso vključile bolnikov z eGFR < 45 ml/min/1,73 m2; 79 bolnikov, izpostavljenih sotagliflozinu, je imelo eGFR
English: These are the signs and symptoms of diabetic ketoacidosis (see also section 2 under ‘Warnings and precautions'):
Slovenian: Diabetično ketoacidozo (DKA), ki je pogosta (pojavi se lahko pri največ 1 od 100 oseb) To so lahko znaki in simptomi diabetične ketoacidoze (glejte tudi poglavje 2, "Opozorila in previdnostni ukrepi"):
English: • yeast infection (thrush) of the vagina (signs may include irritation, itching, unusual discharge or odour)
Slovenian: • glivična okužba ("gobice") spolnega uda (med znaki so lahko draženje, srbenje, nenavaden izcedek ali vonj)
English: Please consult the Patient/Carer's Guide for more information discussed with your doctor about taking Zynquista and the risk of DKA.
Slovenian: Za več informacij o jemanju zdravila Zynquista in tveganju za DKA, o čemer ste se pogovarjli z zdravnikom, glejte Vodnik za bolnike/skrbnike,.
English: No dosage adjustment is recommended based on age.
Slovenian: Odmerek sotagliflozina ni treba prilagajati glede na starost.
English: Difference from placebo,
Slovenian: s placebom.
English: The mean BMI was 28 kg/m2 and 32% of patients had SBP ≥ 130 mmHg.
Slovenian: Povprečni ITM je bil 28 kg/m2 in 32 % bolnikov je imelo SKT ≥ 130 mmHg.
English: In the rat study, embryo-lethality, effects on fetal growth along with cardiovascular and skeletal abnormalities were observed at an exposure multiple of 158-times the human exposure at 400 mg/day.
Slovenian: V študiji na podganah so pri izpostavljenosti, ki je bila 158-kratnik izpostavljenosti človeka med uporabo odmerka 400 mg/dan, opažali embrioletalnost, učinke na rast plodov in srčno-žilne in skeletne nepravilnosti.
English: The patient should be informed: - how to recognize the risk factors which can predispose to ketosis and DKA (including, but not limited to, recent or recurrent history of DKA, missed or reduced insulin doses, decreased caloric intake or severe dehydration, vigorous exercise, intercurrent illness, surgery, alcohol abuse, and in patients using an insulin infusion pump, insulin infusion interruption), - how to recognize DKA signs or symptoms, emphasizing that DKA could occur even when blood glucose levels are below 14 mmol/L (250 mg/dL), - when to discontinue sotagliflozin therapy (see section 4.2), - what actions to take when ketosis/DKA is suspected.
Slovenian: Bolnike je treba poučiti: - kako prepoznajo dejavnike tveganja, ki lahko povečajo nagnjenost h ketozi in DKA (takšni so med drugim nedavna ali ponavljajoča se DKA, izpuščeni ali zmanjšani odmerki insulina, manjši kalorični vnos ali huda dehidracija, naporna telesna dejavnost, trenutne bolezni, kirurški poseg, zloraba alkohola ter, pri uporabnikih insulinske črpalke, prekinitev dovajanja insulina),
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON with blue box
Slovenian: PODATKI NA ZUNANJI OVOJNINI ZUNANJA ŠKATLA s podatki za modro okence
English: Renal function abnormalities (increased serum creatinine and decreased eGFR) can occur after initiating sotagliflozin (see section 4.8).
Slovenian: Po uvedbi sotagliflozina se lahko pojavijo nepravilnosti delovanja ledvic (zvišan kreatinin v serumu in zmanjšanje eGFR) (glejte poglavje 4.8).
English: - Correction of volume depletion prior to initiation of sotagliflozin is recommended in patients with this condition (see section 4.4).
Slovenian: - Pred uvedbo sotagliflozina je priporočljivo bolnikom s hipovolemijo odpraviti motnjo (glejte poglavje 4.4).
English: mL/min/1.73 m2) that sotagliflozin exposures were 1.5 fold higher compared to subjects with normal renal function.
Slovenian: ≥ 45 in < 60 ml/min/1,73 m2) pokazal izpostavljenost sotagliflozinu, ki je bila za ene in druge 1,5-krat večja kot pri preiskovancih z normalnim delovanjem ledvic.
English: DKA may occur in patients treated with Zynquista even if blood glucose levels are below 14 mmol/l (250 mg/dl).
Slovenian: Pri bolnikih, ki prejemajo zdravilo Zynquista, se DKA lahko pojavi, tudi če imajo koncentracijo glukoze v krvi pod 14 mmol/l (250 mg/dl).
English: • Patients with euglycaemic DKA should receive glucose, insulin and fluids for DKA management, sotagliflozin should be discontinued.
Slovenian: • Bolniki z evglikemično DKA morajo za obvladovanje DKA prejemati glukozo, insulin in tekočine; z uporabo sotagliflozina je treba prenehati.
English: No dose adjustment is needed in patients with mild hepatic impairment.
Slovenian: Bolnikom z blago jetrno okvaro odmerka ni treba prilagajati.
English: Mean increases in serum creatinine from baseline to week 4 was 4.0%, 4.3% and 1.4% for sotagliflozin 200mg, sotagliflozin 400 mg and placebo, respectively.
Slovenian: Povprečno zvišanje kreatinina v serumu od izhodišča do 4. tedna je bilo 4,0 % z 200 mg sotagliflozina, 4,3 % s 400 mg sotagliflozina in 1,4 %
English: Post-marketing cases of necrotising fasciitis of the perineum, (also known as Fournier's gangrene), have been reported in female and male patients taking other SGLT2 inhibitors.
Slovenian: Pri bolnicah in bolnikih, ki so jemali druge zaviralce SGLT2, so v obdobju po prihodu zdravila na trg poročali o primerih nekrotizirajočega fascitisa perineja (imenovanega tudi Fournierjeva gangrena).
English: A lower dose of insulin may be required to minimise the risk of hypoglycaemia when used in combination with sotagliflozin (see section 4.2).
Slovenian: Ob sočasni uporabi sotagliflozina je potreben manjši odmerek insulina, da zmanjšamo tveganje za hipoglikemijo (glejte poglavje 4.2).
English: - It is recommended that patients obtain several baseline blood or urine ketone levels over one to two weeks prior to initiation of sotagliflozin therapy, and, patients should become familiar with how their behaviours and circumstances affect their ketone levels.
Slovenian: - Priporočljivo je, da bolniki v enem do dveh tednih pred uvedbo zdravljenja s sotagliflozinom večkrat opravijo meritev izhodiščne vrednosti ketonov v krvi ali urinu.
English: At screening the HbA1c was 8.42%, 8.35% and 8.38% for insulin, insulin+sotagliflozin 200 mg and insulin+sotagliflozin 400 mg.
Slovenian: HbA1c v skupini z insulinom 8,42%, v skupini z insulinom + 200 mg sotagliflozina 8,35 % in v skupini z insulinom + 400 mg sotagliflozina je bil HbA1c 8,38 %.
English: Discontinuation due to genital mycotic infections occurred in 0%, 0.4% and 0.4% of patients treated with sotagliflozin 200 mg, sotagliflozin 400 mg and placebo, respectively.
Slovenian: Delež prenehanja uporabe zdravila zaradi mikotičnih okužb spolovil je bil 0 %, 0,4 % in 0,4 % med prejemniki 200 mg sotagliflozina, 400 mg sotagliflozina in med prejemniki placeba.
English: > 3.0 mmol/L
Slovenian: Verjetna DKA > 3,0 mmol/l